Retatrutide: The Complete 2026 Guide
Retatrutide is an experimental triple-hormone-receptor agonist from Eli Lilly that produced up to ~24% mean weight loss in a phase-2 trial — the highest yet seen from a GLP-1-class drug. It’s not yet approved or available by prescription. Here’s what it is, how it works, the results, the risks, and how it compares to what you can get today.
Retatrutide is a once-weekly injectable that activates three hormone pathways — GLP-1, GIP and glucagon — to reduce appetite and increase energy use. In Lilly’s phase-2 obesity trial it reached about 24% mean body-weight reduction at 48 weeks, ahead of current approved GLP-1 drugs. It is still in clinical development, so it cannot be legally prescribed or bought for human use yet.
A triple agonist — one step beyond tirzepatide
Most GLP-1 weight-loss drugs act on one or two hormone receptors. Retatrutide acts on three. It combines GLP-1 and GIP activity (like tirzepatide) with a third target, glucagon, which is thought to raise energy expenditure on top of appetite suppression. That extra mechanism is the leading explanation for its standout trial results.
It’s given as a once-weekly subcutaneous injection and, like the rest of the class, is titrated upward slowly to keep side effects manageable.
What the trial actually showed
In the phase-2 study (NEJM, 2023), the highest 12 mg dose produced roughly 24% mean weight loss at 48 weeks — and weight was still trending down when the study ended, suggesting the ceiling may be higher. Results rose with dose:
| Target dose | Approx. mean weight loss (48 wks) |
|---|---|
| 1 mg | ~8–9% |
| 4 mg | ~17% |
| 8 mg | ~17–18% |
| 12 mg | ~24% |
For the full titration schedule and dosing detail, see the retatrutide dosage guide.
Side effects and risks
The main side effects are gastrointestinal — nausea, diarrhea, vomiting and constipation — and they rose with dose. A modest heart-rate increase was also observed. Because retatrutide isn’t approved, its long-term safety is still being studied, and any product sold online outside a trial is unregulated with no purity or dose guarantee. Full detail is in the side effects guide.
Not as an approved medication. The only legitimate routes are enrolling in a clinical trial or waiting for approval. Online “research peptide” sellers exist but are unregulated and sold for laboratory use only — see where to buy retatrutide for the full reality. If you want supervised weight-loss treatment now, approved GLP-1s are the practical path.
Start with a GLP-1 you can actually get
Semaglutide and tirzepatide are approved, prescribable and available through licensed providers today. Compare the top-rated options.
Retatrutide resources
- Retatrutide dosage guide — escalation chart, weight loss by dose, reconstitution
- Retatrutide side effects — what trials show and how to read them
- Retatrutide vs tirzepatide — results, mechanism and availability
- Retatrutide dosage calculator — reconstitution & units tool
- Where to buy retatrutide — the honest availability answer
Retatrutide: frequently asked questions
Is retatrutide the same as Ozempic?
Where can you get retatrutide?
What are the risks of using retatrutide?
How long does retatrutide take to work?
Editor’s picks from our full vendor review. We may earn a commission — it never changes your price.
-
#1
ZevayStreamlined GLP-1 telehealth
Visit site -
#2
ReadyRxFast approvals on weight-loss meds
Visit site -
#3
TrimRxPersonalized programs, US pharmacies
Visit site